Pharma News

Pfizer Inc announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM). Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb).

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunisation for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions.

RSV is a common and highly contagious seasonal virus, infecting nearly all children by the age of two.

Indian Pharmacopoeia Commission clarifies on three new general chapters introduced in Indian Pharmacopoeia 2022 which are on Uniformity of Dosage Units, Elemental Impurities and Nitrosamine Impurities.

Indian Pharmacopoeia Commission (IPC) has published the Indian Pharmacopoeia (IP) 2022 and Hon ble Union Health Minister released the 9th edition of IP 2022 in July, 2022 in Vigyan Bhawan. New Delhi.

In-Cosmetics Asia 2022 Exhibition & Conference was held in Bangkok, Thailand from 1st to 3rd November 2022. It is regarded as an annual meeting hub for the Asia Pacific cosmetic and personal care industry, bringing together exhibiting ingredient suppliers and visiting manufacturers keen to source ingredients, learn, network and do business. This is where all areas of the cosmetics industry connect to inspire, share insights and spark potential collaborations.

For the first time Sun Pharma secured the top position by doctor prescriptions. It outperforms Mankind Pharma long stand, according to market research firm, SMSRC.

Sun Pharma is the largest Indian pharma company by capital, but Mankind Pharma was leading market rank for number of doctor prescriptions for a long time. Recently as per market research firm, SMSRC, Sun Pharma, which has topped India’s pharma retail market for years, has now become the leader in prescriptions, bolstered by an increase in field force and a sharper focus on core therapies.

In patients meeting the eligibility requirements for the DAPA-CKD trial, dapagliflozin is likely to be a cost effective treatment within the UK, German, and Spanish health care systems, as per new research.

Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumour. This means that immune cells cannot reach the cancer cells to remove them. The scientific community has been working for years to increase the effectiveness of the immune system against cancer by using vaccines based on dead tumour cells.

The unreasonable use of antibiotics has pushed bacteria to develop resistance mechanisms to this type of treatment. This phenomenon, known as antibiotic resistance, is now considered by the WHO as one of the greatest threats to health. The lack of treatment against multi-resistant bacteria could bring us back to a time when millions of people died of pneumonia or salmonella. The bacteriumKlebsiella pneumoniae, which is very common in hospitals and particularly virulent, is one of the pathogens against which our weapons are becoming blunt.

Cipla Limited gets unaudited consolidated financial results for quarter ended September 30th, 2022. Differentiated pipeline unlocking and continued One-India momentum drive core revenue growth of 12 pc and expansion in EBITDA margin.

Revenue growth for the quarter was at 6 pc on a reported basis and a strong 12% on a covid adjusted base of last year; One-India Robust traction in core portfolio across therapies and business segments; 15 pc YoY ex-covid growth.